Passoke Sarah, Stern Carlotta, Häußler Vivien, Kümpfel Tania, Havla Joachim, Engels Daniel, Jarius Sven, Wildemann Brigitte, Korporal-Kuhnke Mirjam, Senel Makbule, Stellmann Jan-Patrick, Warnke Clemens, Grothe Matthias, Schülke Rasmus, Gingele Stefan, Kretschmer Julian Reza, Klotz Luisa, Walter Annette, Then Bergh Florian, Aktas Orhan, Ringelstein Marius, Ayzenberg Ilya, Schwake Carolin, Kleiter Ingo, Sperber Pia Sophie, Rust Rebekka, Schindler Patrick, Bellmann-Strobl Judith, Paul Friedemann, Kopp Bruno, Trebst Corinna, Hümmert Martin W
Department of Neurology, Hannover Medical School, Hannover, Germany.
University Hospital Innsbruck, Innsbruck, Austria.
J Neurol Neurosurg Psychiatry. 2024 Jul 30;96(3). doi: 10.1136/jnnp-2024-333994.
Data on cognition in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are limited to studies with small sample sizes. Therefore, we aimed to analyse the extent, characteristics and the longitudinal course of potential cognitive deficits in patients with MOGAD.
The CogniMOG-Study is a prospective, longitudinal and multicentre observational study of 113 patients with MOGAD. Individual cognitive performance was assessed using the Paced Auditory Serial Addition Task (PASAT), the Symbol Digit Modalities Test (SDMT) and the Multiple Sclerosis Inventory Cognition (MuSIC), which are standardised against normative data from healthy controls. Cognitive performance was assessed at baseline and at 1-year and 2-year follow-up assessments. Multiple linear regression was used to analyse demographic and clinical predictors of cognitive deficits identified in previous correlation analyses.
At baseline, the study sample of MOGAD patients showed impaired standardised performance on MuSIC semantic fluency (mean=-0.29, 95% CI (-0.47 to -0.12)) and MuSIC congruent speed (mean=-0.73, 95% CI (-1.23 to -0.23)). Around 1 in 10 patients showed deficits in two or more cognitive measures (11%). No decline in cognition was observed during the 1-year and 2-year follow-up period. Cerebral lesions were found to be negatively predictive for SDMT (B=-8.85, 95% CI (-13.57 to -4.14)) and MuSIC semantic fluency (B=-4.17, 95% CI (-6.10 to -2.25)) test performance.
Based on these data, we conclude that MOGAD patients show reduced visuomotor processing speed and semantic fluency to the extent that the disease burden includes cerebral lesions.
关于髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）患者认知功能的数据仅限于小样本研究。因此，我们旨在分析MOGAD患者潜在认知缺陷的程度、特征及纵向病程。
CogniMOG研究是一项针对113例MOGAD患者的前瞻性、纵向、多中心观察性研究。使用听觉系列加法任务（PASAT）、符号数字模态测验（SDMT）和多发性硬化症认知量表（MuSIC）评估个体认知表现，这些量表均根据健康对照的标准数据进行了标准化。在基线、1年和2年随访评估时评估认知表现。采用多元线性回归分析先前相关性分析中确定的认知缺陷的人口统计学和临床预测因素。
在基线时，MOGAD患者的研究样本在MuSIC语义流畅性（均值=-0.29，95%可信区间（-0.47至-0.12））和MuSIC一致性速度（均值=-0.73，95%可信区间（-1.23至-0.23））方面表现出标准化表现受损。约十分之一的患者在两项或更多认知测量中存在缺陷（11%）。在1年和2年随访期间未观察到认知功能下降。发现脑损伤对SDMT（B=-8.85，95%可信区间（-13.57至-4.14））和MuSIC语义流畅性（B=-4.17，95%可信区间（-6.10至-2.25））测试表现具有负向预测作用。
基于这些数据，我们得出结论，MOGAD患者在疾病负担包括脑损伤的情况下，视觉运动处理速度和语义流畅性降低。
